Key result
Low-dose aspirin was associated with an increased risk of non-fatal upper (OR 1.62; 95% CI 1.42-1.86) and lower (OR 1.63; 95% CI 1.47-1.81) gastrointestinal bleeding, but not fatal bleeding.
Why the study?
Risks of low-dose aspirin-associated upper and lower gastrointestinal bleeds may vary by severity and cardiovascular disease status, but no study had quantified these risks in the same real-world population.
Does low-dose aspirin increase the risk of upper and lower gastrointestinal bleeding by severity in primary and secondary CVD prevention?
Cohort (n=398,098)
Does low-dose aspirin increase the risk of upper and lower gastrointestinal bleeding by severity in primary and secondary CVD prevention?
Odds Ratio: 1.62 (95% CI 1.42–1.86)
Low-dose aspirin is associated with an increased risk of non-fatal, but not fatal, upper and lower gastrointestinal bleeding in real-world primary care patients.
No takes yet. Share an insight, caveat, or question.
Low-dose aspirin may warrant closer non-fatal GIB surveillance in primary care; leaves open fatal risk differences by CVD prevention setting.
Rodrı́guez et al. (2019) reported a cohort. Low-dose aspirin vs. non-use was evaluated on non-fatal upper gastrointestinal bleed (UGIB) (OR 1.62, 95% CI 1.42-1.86). Low-dose aspirin was associated with an increased risk of non-fatal upper (OR 1.62; 95% CI 1.42-1.86) and lower (OR 1.63; 95% CI 1.47-1.81) gastrointestinal bleeding, but not fatal bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: